Published online before print August 16, 2001, doi: 10.1161/hh1701.095642
© 2001 American Heart Association, Inc.
Clinical Research |
Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis
From the Molecular Signaling Section, Laboratory of Host Defenses of the National Institute of Allergy and Infectious Diseases (D.H.M., M.N.M, P.M.M.) and the Cardiology Branch (J.P.J.H., W.H.S., N.E., A.A.Q.) and the Office of Biostatistics Research (M.A.W.) of the National Heart, Lung, and Blood Institute, NIH, Bethesda, Md.
Correspondence to Dr Philip M. Murphy, Bldg 10, Room 11N113, NIH, Bethesda, MD 20892. E-mail pmm{at}nih.gov
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Fractalkine, a chemokine expressed by inflamed endothelium, induces leukocyte adhesion and migration via the receptor CX3CR1, and the CX3CR1 polymorphism V249I affects receptor expression and function. Here we show that this polymorphism is an independent risk factor for atherosclerotic coronary artery disease (CAD). Genotyping of the CX3CR1-V249I polymorphism was performed in a cohort of 339 white individuals who underwent cardiac catheterization (n=197 with and n=142 without CAD, respectively). In 203 patients, intracoronary acetylcholine 15 µg/min) and sodium nitroprusside (20 µg/min) were administered to test endothelium-dependent and -independent coronary vascular function, respectively. Change in coronary vascular resistance (
CVR) was measured as an index of microvascular dilation. An association was observed between presence of the CX3CR1 I249 allele and reduced prevalence of CAD, independent of established CAD risk factors (odds ratio=0.54 [95% confidence interval, 0.30 to 0.96], P=0.03). Angiographic severity of CAD was also lower in these subjects (P=0.01). Furthermore, endothelium-dependent vasodilation was greater in these individuals compared with individuals homozygous for the CX3CR1-V249 allele (CVR during acetylcholine = -46±3% versus -36±3%, respectively, P=0.02), whereas CVR with sodium nitroprusside was similar in both groups (-55±2% versus -53±2%, P=0.45). The association between CX3CR1 genotype and endothelial function was independent of established risk factors and presence of CAD by multivariate analysis (P=0.02). Thus, the CX3CR1 I249 allele is associated with decreased risk of CAD and improved endothelium-dependent vasodilation. This suggests that CX3CR1 may be involved in the pathogenesis of CAD.
Key Words: genetics • fractalkine • acetylcholine • inflammation • epidemiology
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Atherosclerotic coronary artery disease (CAD) is a multifactorial process that involves inflammation in response to progressive vascular injury.1 Vascular endothelium plays a key role in this process by secreting factors that can directly regulate vascular tone, induce accumulation and activation of platelets and leukocytes at the vessel wall, and cause proliferation of vascular smooth muscle cells.2,3 Hypertension, diabetes, smoking, and hypercholesterolemia are established risk factors for CAD and appear to work in part by causing endothelial injury, resulting in reduced bioavailability of NO. This state can be clinically characterized by demonstrating impaired vasodilation in response to endothelium-dependent pharmacological probes such as acetylcholine (ACH).4–6 In vivo measurement of coronary vascular endothelial function not only correlates with coronary vasomotion during physiological stress, but also appears to be an independent predictor of long-term progression of atherosclerosis and adverse cardiovascular events.3,7
Genetic factors also appear to be important determinants of cardiovascular disease.8–11 In particular, specific genetic polymorphisms that modulate blood pressure, coagulation, and lipid metabolism have been identified that are associated with increased risk of CAD.12–17 However, none of these associations has identified the precise molecular basis of pathological accumulation of leukocytes in the vessel wall.
In general, leukocyte trafficking is regulated by specific sets of adhesion molecules, chemoattractants, and chemoattractant receptors. The chemokines are a large family of chemoattractant peptides that differentially attract subsets of leukocytes.18,19 Several chemokines have been identified in atherosclerotic lesions, and experiments in knockout mice have revealed a role for one of these, monocyte chemoattractant protein-1 (MCP-1), and its receptor CCR2 (CC chemokine receptor 2).20–22 However, the importance of chemokines in human CAD has not been established.
Fractalkine (CX3CL1 in the systematic chemokine nomenclature)19 is an unusual chemokine markedly upregulated on inflamed endothelium that can function as a chemoattractant and a direct adhesin via its specific receptor CX3CR1. CX3CR1 is expressed on monocytes, T lymphocytes, and natural killer (NK) cells.23 We have previously reported two common nonsynonymous single nucleotide polymorphisms of CX3CR1 that are in complete linkage disequilibrium (V249I and T280M).24,25 The I249 allele has been associated with reduced number of fractalkine binding sites and reduced fractalkine binding affinity on peripheral blood mononuclear cells, as well as with reduced risk for acute coronary events, suggesting that CX3CR1 may participate in the pathogenesis of atherosclerosis by affecting fractalkine-mediated inflammatory events.26 Here we further test this hypothesis by analyzing the association of CX3CR1 polymorphism with angiographically defined atherosclerosis and coronary vascular function.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Study Subjects
We studied all 339 white subjects enrolled as of April 2000 in an ongoing clinical protocol to evaluate coronary vascular function. Inclusion criteria for entry to the protocol were chest pain or noninvasive tests consistent with myocardial ischemia and age greater than 21. Patients with significant valvular heart disease and those with recent unstable angina or myocardial infarction were excluded from enrollment. All enrolled subjects underwent cardiac catheterization. A subset of these (n=203) who consented to the procedure and did not have safety exclusion criteria (left main stem disease or 3-vessel disease in whom it would be unsafe to instrument any coronary artery) and were able to tolerate withdrawal of cardiac medications also underwent endothelial function tests. The National Heart, Lung, and Blood Institute Investigational Review Board approved the study, and informed consent for catheterization and genotyping was obtained from all patients.
Clinical Definitions
CAD was defined as angiographic evidence of stenosis in any epicardial coronary artery of 
50%. Conversely, a participant was defined as having no significant CAD if all epicardial coronary arteries had <50% stenoses.27 We also studied the subgroup with angiographically smooth coronary arteries (n=117) versus those with any evidence of plaquing or stenosis (n=222). CAD severity was defined as the number of major epicardial coronary vessels with angiographic evidence of one or more stenoses of 50% severity. Risk factors for atherosclerosis that were analyzed included age, male gender, body mass index, tobacco smoking, diabetes, hypercholesterolemia, and hypertension. Smoking was defined as a current or a prior history of tobacco use. Diabetes was defined as a fasting blood glucose level >7.8 nmol/L (140 mg/dL), or treatment with dietary modification, insulin, or oral hypoglycemic agents at the time of the study. Hypertension was defined as a seated systolic blood pressure 140 mm Hg and/or diastolic pressure 90 mm Hg on at least three occasions, or if such a diagnosis had been made in the past and the patient was being treated with medication or lifestyle modification. Hypercholesterolemia was defined as a fasting cholesterol 6.2 mmol/L (240 mg/dL) or treatment with lipid-lowering medication. Clinical characteristics are shown in Table 1.
|
Cardiac Catheterization Protocol
All subjects enrolled in the protocol underwent diagnostic coronary angiography using standard techniques. Two hundred three of these patients subsequently underwent assessment of coronary vascular function. In these subjects, all cardiac medications were withdrawn 48 hours before the study, and aspirin or other cyclo-oxygenase inhibitors were discontinued 7 days before. After diagnostic coronary angiography, a 3F infusion catheter was introduced using a 7F guiding catheter into the aortocoronary ostium of a major epicardial artery, and blood flow velocity was measured, as previously described, using a 0.014- or 0.018-inch wire equipped with a Doppler crystal at its tip (FloWire, EndoSonics).5,28,29
Coronary blood flow was measured and coronary vascular resistance (CVR) was calculated during intracoronary infusions of ACH followed by sodium nitroprusside and then adenosine, to test endothelium-dependent and -independent coronary microvascular function and vasodilator reserve, respectively.5,28,29 Further details of the coronary vascular function testing protocol are provided in the online data supplement available at http://www.circresaha.org.
Genotyping
Laboratory personnel who had no knowledge of the coronary angiographic or vascular function data performed CX3CR1 genotyping. The following two CX3CR1 polymorphisms have been identified: I249, a guanine-to-adenine substitution at nucleotide 745 of the open reading frame changing valine at position 249 in the reference sequence to isoleucine, and M280, a cytosine-to-thymidine substitution at nucleotide 839 changing a threonine at position 280 in the reference sequence to methionine.24,25 These two variants are in complete linkage disequilibrium such that there are only 3 haplotypes and 6 compound genotypes of the 4 and 9 that are possible, respectively. Further details of our CX3CR1 genotyping protocol are provided in the online supplement available at http://www.circresaha. org. A third chemokine receptor polymorphism, CCR532, was genotyped as previously described.30
Statistical Analysis
Data are mean±SEM, and differences between means were compared by the 2-tailed unpaired Student t test. Univariate correlations were performed by use of the Pearson correlation coefficient. Differences in genotypic frequencies for the CX3CR1 and CCR532 polymorphisms were examined for significance using the Pearson 
2 test. The independent contribution of CX3CR1 genotype to the presence of CAD was determined using a stepwise logistic regression model with traditional CAD risk factors such as age, male gender, body mass index, cigarette smoking, diabetes, hypercholesterolemia, and hypertension entered as covariates, and the odds ratio was calculated using this model (the Logistic procedure of SAS).31 The association between genotype and severity of CAD was determined using the Mann-Whitney U test. To identify predictors of change in CVR with ACH in a multivariate setting, we used multiple linear regression (General Linear Model Procedure of SAS) on the regressors age, sex, body mass index, smoking, hypercholesterolemia, presence of CAD, hypertension, diabetes, or the CX3CR1 genotype (as presence or absence of the CX3CR1 249I allele).
An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Association Between CAD and Established Risk Factors
Of the 339 white subjects studied, 197 had CAD, and 142 did not (117 of these had smooth-appearing coronary arteries, and 25 had evidence of mild plaquing). By univariate analysis, increasing age, male gender, hypercholesterolemia, hypertension, diabetes, and smoking were significantly associated with the presence of CAD (Table 1). Age, male gender, hypercholesterolemia, diabetes, and smoking remained as independent risk factors for CAD after multivariate analysis (Table 1).
Distribution of CX3CR1 Genotypes in Study Participants
Consistent with our previously published results, we found that the CX3CR1-V249I and -T280M polymorphisms were in complete linkage disequilibrium such that there are only three haplotypes and 6 genotypes (Table 2).24,25 Fifty-seven percent of our white subjects were CX3CR1-V249 homozygotes (genotype 1) as compared with 53% of 176 white random blood donors, as previously reported.25 The proportion of genotypes for each allele considered separately was consistent with Hardy-Weinberg predictions for all groups.
|
Association of CX3CR1 Genotype With CAD
It has been previously demonstrated that CX3CR1 expression and fractalkine binding affinity on peripheral blood mononuclear cells are greater for CX3CR1-V249 homozygotes (genotype 1) compared with those with the CX3CR1 I249 allele,26 and given the limited numbers of individuals in genotypes 2 to 4, we compared individuals with genotype 1 with all other genotypes as a combined group (genotypes 2 to 6, Table 2). Thus our primary comparisons are limited to subjects homozygous for the V249 allele compared with those heterozygous or homozygous for the I249 allele.
Individuals with an I249 allele were less frequent in the CAD group compared with those without CAD (38% versus 51%, univariate odds ratio=0.74 [95% confidence interval, 0.58 to 0.95], P=0.03, Table 2). Established cardiac risk factors were very similar in both genotype subgroups (Table 3), and the observed association between CX3CR1 genotype and presence of CAD remained significant after multivariate adjustment for established CAD risk factors (odds ratio=0.54 [0.30 to 0.96], P=0.03, Table 1). We also compared only those 117 subjects with angiographically smooth coronary arteries versus all others (n=222). Individuals with an I249 allele were also less frequent among those with angiographic evidence of atherosclerosis (40% versus 50%, univariate odds ratio=0.65 [0.41 to 1.01], P=0.06; adjusted odds ratio=0.58 [0.32 to 1.07], P=0.08). Angiographic severity of atherosclerosis was also less in subjects with an I249 allele compared with subjects homozygous for the V249 allele (mean number of diseased vessels, 1.07±0.10 versus 1.42±0.09, respectively, P=0.01, Figure 1). Consistent with the complete linkage disequilibrium of I249 and M280, we found that individuals with an M280 allele were also less frequent in the CAD group compared with those without CAD (23% versus 35%, univariate odds ratio=0.58 [95% confidence interval, 0.36–0.93], P=0.03).
|
|
CX3CR1 Genotype and Coronary Endothelial Function
Endothelium-dependent coronary microvascular dilation with ACH was greater in subjects with an I249 allele compared with V249 homozygotes (P=0.02, Figure 2). Thus, subjects with an I249 allele had a 27% greater fall in CVR in response to ACH than V249 homozygotes. Moreover, when the population was divided into two equal groups with either "normal" (mean CVR=-62±1%) or "depressed" (mean CVR=-20±3%) response to ACH, the proportion of subjects with an I249 allele was lower in those with depressed compared with those with normal endothelial function (35% versus 54%, respectively, P=0.01).
|
Univariate predictors of endothelial function, measured as percentage reduction in CVR with ACH, were age (P=0.01), presence of CAD (P=0.009), smoking (P=0.01), and the CX3CR1-V249I polymorphism (P=0.02). By multivariate analysis, smoking (P=0.03) and the CX3CR1-V249I polymorphism (P=0.02) remained significant predictors of the ACH response, independent of all other risk factors for endothelial dysfunction including the presence of CAD. In contrast, microvascular vasodilation observed during infusions of the endothelium-independent vasodilators sodium nitroprusside and adenosine was similar in patients with and without the I249 allele (Figure 2). Furthermore, when we defined CAD as any visible plaquing or stenosis, after multivariate adjustment the independent relationship between the I249 allele and better vasodilation in response to ACH remained (P=0.015). There was no significant difference between the genotypes with respect to sodium nitroprusside or adenosine responsiveness (P=0.32 and P=0.97, respectively).
CCR532 Genotype, Coronary Atherosclerosis, and Coronary Vascular Function
We also stratified study participants on the basis of the CCR532 polymorphism in the CCR5 gene, which encodes another chemokine receptor. This mutation is a 32-bp deletion in the CCR5 open reading frame that prevents expression of CCR5 on the cell surface. Like CX3CR1, CCR5 is also expressed on lymphocytes and monocytes. CCR532 is found at an allele frequency of 10% in North American whites.30,32
In this cohort, the frequency of the CCR532 allele was 10% and the genotypes were in Hardy-Weinberg equilibrium. The frequency of subjects heterozygous or homozygous for the CCR532 allele was similar in the CAD and NSCAD groups (18% versus 16%, P=0.63). Likewise, the change in CVR in response to ACH was similar in subjects without compared with those with the CCR532 allele (CVR= -41±2% versus -41±5% respectively, P=0.84), as were the responses to sodium nitroprusside (CVR= -54±2% versus -53±4% respectively, P=0.94) and adenosine (CVR= -72±1% versus -73±2% respectively, P=0.88).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The major findings of this study are that human subjects with the fractalkine receptor, CX3CR1 I249 allele have a reduced risk of developing CAD and have less severe disease than individuals homozygous for the CX3CR1-V249 reference allele. Endothelium-dependent, but not independent, coronary vasodilation is also better in subjects with the I249 allele. Thus, presence of the I249 allele was associated with lower risk of both structural (presence and angiographic severity of atherosclerosis) and functional (endothelium-dependent vasodilation) measures of atherogenesis. In contrast, CCR5
32, a mutation that inactivates the chemokine receptor CCR5, did not affect risk of coronary endothelial dysfunction or atherosclerosis. This does not support a role for CCR5 in human atherosclerosis.
CX3CR1 Genotype and CAD
CAD is a complex multifactorial process that involves an inflammatory/immune response to ongoing vascular injury that may be metabolic, physical, infectious, oxidative, and/or autoimmune in origin.1 Nonspecific markers of systemic inflammation such as C-reactive protein, fibrinogen, and white blood cell levels are positively associated with the risk of CAD.9 Immune responses are also implicated in the increased atherosclerotic risk associated with exposure to pathogens capable of chronic infections such as Chlamydia pneumoniae and cytomegalovirus and autoimmune factors such as the presence of antibodies to human heat shock protein-60 and oxidized LDL.33–37 Atherosclerotic lesions contain a prominent leukocytic infiltrate consisting primarily of monocytes, monocyte-derived macrophages, and CD4+CD45RO+ memory T cells.38 Leukocyte trafficking is mediated by a number of factors including adhesion molecules, such as vascular cellular adhesion molecule-1, intercellular adhesion molecule-1 (ICAM-1), and E-selectin, and chemokines such as interleukin (IL)–8 and MCP-1.38
The role of fractalkine and CX3CR1 in leukocyte trafficking in vivo is not yet clear, although unambiguous effects on both chemotaxis and cell adhesion have been shown in vitro.23 Fractalkine is an unusual chemokine in that it possesses a transmembrane domain and seems to mediate a particularly strong and rapid flow arrest of cells such as resting monocytes, IL-2–activated CD8+ T lymphocytes, and NK cells on endothelial cells.23 Fractalkine can also be cleaved to release a free chemokine domain that stimulates monocyte, NK cell, and T-lymphocyte chemotaxis.23,39,40 Fractalkine-mediated adhesion does not require G-protein activation or integrin upregulation.41,42 Inflammatory cytokines such as tumor necrosis factor-
, IL-1ß, and lipopolysaccharide markedly upregulate endothelial expression of fractalkine via a nuclear factor 
B–dependent mechanism, and fractalkine-mediated adhesion of circulating NK cells leads to endothelial cell injury, an effect that can be blocked by soluble fractalkine or anti-CX3CR1 antibody.43–45 Furthermore, fractalkine enhanced adhesion of macrophage-like THP-1 cells and monocytes to fibronectin and ICAM-1 presumably via CX3CR1-mediated signaling.46 These properties suggest that any factor that modulated CX3CR1 expression level and/or affinity for ligand may affect leukocyte trafficking and associated disease processes, including atherosclerosis. In this regard, it is noteworthy that the CX3CR1 alleles that we have analyzed in the present study have already been reported to differ in both these parameters.24,26
CX3CR1 Genotype and Coronary Vascular Function
Coronary vasodilation in response to ACH is predominantly due to stimulation of NO release.5,47,48 Depression of this response is a marker of an impaired vasodilator response during physiological stress, increased platelet aggregability, an accelerated progression of atherosclerosis, and an adverse cardiovascular prognosis.2,3,5,7 In experimental animal models, reduced NO bioavailability and endothelial dysfunction precipitate accelerated atherosclerosis, and increased oxidative stress associated with exposure to risk factors reduces NO bioavailability and promotes vascular inflammation. Moreover, endothelium-dependent vasodilator capacity is depressed in patients with evidence of increased systemic inflammation.49–52 Thus, factors that facilitate the inflammatory process would be expected to contribute to endothelial dysfunction. We observed that endothelium-dependent coronary vasodilation is greater in subjects with the CX3CR1 I249 allele, and that this genotype predicts the endothelium-dependent coronary vasodilator response to ACH, independently of the presence of CAD and other risk factors for endothelial dysfunction. Potential mechanisms for this finding, supported by current experimental evidence, include direct NK cell–mediated endothelial cell injury and/or increased leukocyte adhesion and infiltration into the vascular wall facilitated by increased expression and fractalkine binding affinity of CX3CR1 in V249 homozygotes.24,45,46 In contrast, the coronary vascular responses to the endothelium-independent vasodilators adenosine and sodium nitroprusside were similar, indicating equivalent smooth muscle vasodilator capacity in both genotypic subsets. This further supports our hypothesis that reduction in vasodilator response to ACH associated with CX3CR1-V249 reflects a selective decrease in endothelial function and not a generalized abnormality of vasodilator tone. These observations are consistent with our findings of endothelial dysfunction in subjects homozygous for V249, independent of the presence of angiographic evidence of CAD, and provide a mechanistic insight into the potential role of fractalkine and the CX3CR1 receptor in the pathogenesis of endothelial dysfunction and atherosclerosis.
Limitations
Additional independent studies of atherosclerosis and endothelial function as endpoints will be needed to confirm the present study. We limited our analysis to white participants because we had found previously that the frequencies of both variants are not equivalent in different racial groups.25 Further studies will also be needed to address the impact of these polymorphisms in other racial groups. Our cohort was not designed to test whether CX3CR1 polymorphism is a risk factor for acute clinical coronary events; however, our recent study of a myocardial infarction/unstable angina cohort from France, which has been reported separately, has demonstrated this.26 Importantly, the relative risk for acute coronary events attributable to possession of 249I in that study was similar to that for atherosclerosis reported here. That study did not report angiographic and endothelial function parameters.26 Thus, the two studies are complementary and consistent.
As in any genetic association study, it is difficult to completely ensure that the result is not secondary to another closely linked site. The disease association with I249 reported here may be influenced by M280 or other as-yet-unknown variants in the CX3CR1 gene promoter. Some of the CX3CR1 genotypes are rare, making epidemiological conclusions difficult except in the largest cohorts, and even in the largest studies, the linkage disequilibrium of M280 with I249 makes it difficult to distinguish the independent contribution of the M280 polymorphism to CAD risk.
Finally, we have not analyzed epicardial coronary arterial vascular function in this study because of the well-known heterogeneous segmental response of epicardial vessels to ACH.53 In contrast, CVR measurements reflect vascular tone in all resistance vessels subtended by the infused vessel and provide a more complete measurement of endothelial function in that vascular territory. Moreover, a close relationship exists between epicardial and microvascular reactivity to endothelium-dependent and -independent agonists.5
Conclusions
We have demonstrated an independent association between CX3CR1 genotype and prevalence and severity of CAD, and endothelial dysfunction in white subjects. Our findings suggest that subjects with the CX3CR1 I249 allele have a reduced risk of developing atherosclerosis as a consequence of improved endothelial function probably as a result of a lower susceptibility to vascular inflammation. This suggests that fractalkine-CX3CR1 interaction may be a useful target for designing future therapies for CAD.
|
Footnotes |
|---|
*Both authors contributed equally to this study.
Received March 19, 2001; accepted July 5, 2001.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. . 1999; 340: 115–126.
2. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med. . 1998; 105: 32S–39S.
3. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. . 2000; 101: 948–954.
4. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. . 1995; 92: 320–326.
5. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest. . 1995; 95: 1747–1755.
6. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. . 1990; 81: 491–497.
7. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. . 2000; 101: 1899–1906.
8. Motulsky AG, Brunzell JD. The genetics of coronary atherosclerosis. In: King RA, Rotter JI, Motulsky AG, eds. The Genetic Basis of Common Diseases. New York, NY: Oxford University Press; 1992: 150–169.
9. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc. . 2000; 75: 369–380.
10. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. . 1994; 330: 1041–1046.
11. Curtiss LK, Kubo N, Schiller NK, Boisvert WA. Participation of innate and acquired immunity in atherosclerosis. Immunol Res. . 2000; 21: 167–176.
12. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. . 1992; 359: 641–644.
13. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. . 1996; 334: 1090–1094.
14. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, Ogawa H, Harada E, Masuda T, Koyama W, Saito Y, Miyamoto Y, Ogawa Y, Nakao K. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol. . 1998; 31: 1506–1510.
15.
Orth M, Weng W, Funke H, Steinmetz A, Assmann G, Nauck M, Dierkes J, Ambrosch A, Weisgraber KH, Mahley RW, Wieland H, Luley C. Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28
Pro), on lipoproteins and the prevalence of coronary artery disease in whites. Arterioscler Thromb Vasc Biol. . 1999; 19: 1306–1315.
16.
Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor 
C161T polymorphism and coronary artery disease. Cardiovasc Res. . 1999; 44: 588–594.
17. Prasad A, Narayanan S, Husain S, Padder F, Waclawiw M, Epstein N, Quyyumi AA. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation. . 2000; 102: 35–41.
18. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. . 1998; 338: 436–445.
19. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. . 2000; 52: 145–176.
20. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. . 1998; 394: 894–897.
21. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. . 1998; 2: 275–281.
22. Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. . 1999; 143: 205–211.
23. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. . 1997; 385: 640–644.
24. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P, Theodorou I, Combadiere C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science. . 2000; 287: 2274–2277.
25. McDermott DH, Colla JS, Kleeberger CA, Plankey M, Rosenberg PS, Smith ED, Zimmerman PA, Combadiere C, Leitman SF, Kaslow RA, Goedert JJ, Berger EA, O’Brien TR, Murphy PM. Genetic polymorphism in the HIV coreceptor CX3CR1 and risk of HIV disease. Science. . 2000; 290: 2031a.
26. Moatti D, Faure S, Fumeron F, Seknadji P, McDermott DH, Debre P, Aumont MC, Murphy PM, de Prost D, Combadiere C. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. . 2001; 97: 1925–1928.
27. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO. ACC/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. . 2001; 37: 1–24.
28. Dakak N, Husain S, Mulcahy D, Andrews NP, Panza JA, Waclawiw M, Schenke W, Quyyumi AA. Contribution of nitric oxide to reactive hyperemia: impact of endothelial dysfunction. Hypertension. . 1998; 32: 9–15.
29. Li A, Prasad A, Mincemoyer R, Satorius C, Epstein N, Finkel T, Quyyumi AA. Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am J Med Genet. . 1999; 86: 57–61.
30. Zimmerman PA, Buckler WA, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, Cohen O, Rubbert A, Lam G, Vaccarezza M, Kennedy PE, Kumaraswami V, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB, Murphy PM. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med. . 1997; 3: 23–36.
31. SAS Institute, Inc. SAS User’s Guide: Statistics, Version 5. Cary, NC: SAS Institute Inc.; 1985.
32. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O’Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. . 1996; 273: 1856–1862.
33. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation. . 1999; 100: e20–e28.
34. Grayston JT. Does Chlamydia pneumoniae cause atherosclerosis? Arch Surg. . 1999; 134: 930–934.
35. Horvath R, Cerny J, Benedik J, Hokl J, Jelinkova I. The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. J Clin Virol. . 2000; 16: 17–24.
36. Vaarala O. Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. J Intern Med. . 2000; 247: 381–384.
37. Zhu J, Quyyumi AA, Rott D, Csako G, Wu H, Halcox J, Epstein SE. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation. . 2001; 103: 1071–1075.
38. Gerszten RE, Mach F, Sauty A, Rosenzweig A, Luster AD. Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med. . 2000; 136: 87–92.
39. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. . 1997; 91: 521–530.
40. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. . 1997; 387: 611–617.
41. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. . 1998; 188: 1413–1419.
42. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction: rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem. . 1999; 274: 10053–10058.
43. Harrison JK, Jiang Y, Wees EA, Salafranca MN, Liang HX, Feng L, Belardinelli L. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol. . 1999; 66: 937–944.
44.
Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, Bacon KB, Zerwes HG, Feng L. NF-B-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1ß, TNF-, and LPS. J Leukoc Biol. . 2000; 67: 577–584.
45. Yoneda O, Imai T, Goda S, Inoue H, Yamauchi A, Okazaki T, Imai H, Yoshie O, Bloom ET, Domae N, Umehara H. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol. . 2000; 164: 4055–4062.
46. Goda S, Imai T, Yoshie O, Yoneda O, Inoue H, Nagano Y, Okazaki T, Imai H, Bloom ET, Domae N, Umehara H. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol. . 2000; 164: 4313–4320.
47. Quyyumi AA, Dakak N, Mulcahy D, Andrews NP, Husain S, Panza JA, Cannon RO. Nitric oxide activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol. . 1997; 29: 308–317.
48. Quyyumi AA, Mulcahy D, Andrews NP, Husain S, Panza JA, Cannon RO. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. Circulation. . 1997; 95: 104–110.
49. Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock J, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow CP, Chao YS, Rader DJ, Wright SD, Pure E. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. . 2000; 165: 3430–3435.
50. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C -reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. . 2000; 102: 1000–1006.
51. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, Donald AE, Palacios M, Griffin GE, Deanfield JE, MacAllister RJ, Vallance P. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. . 2000; 102: 994–999.
52. Sinisalo J, Paronen J, Mattila KJ, Syrjala M, Alfthan G, Palosuo T, Nieminen MS, Vaarala O. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis. . 2000; 149: 403–411.
53. el-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Kerensky RA, Conti CR, Pepine CJ. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease: endothelial function revisited. Circulation. . 1994; 89: 45–51.
This article has been cited by other articles:
 |
|
 |
|
  Y.-W. Huang, P. Su, G. Y. Liu, M. R. Crow, D. Chaukos, H. Yan, and L. A. Robinson Constitutive Endocytosis of the Chemokine CX3CL1 Prevents Its Degradation by Cell Surface Metalloproteases J. Biol. Chem., October 23, 2009; 284(43): 29644 - 29653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dorgham, A. Ghadiri, P. Hermand, M. Rodero, L. Poupel, M. Iga, O. Hartley, G. Gorochov, C. Combadiere, and P. Deterre An engineered CX3CR1 antagonist endowed with anti-inflammatory activity J. Leukoc. Biol., October 1, 2009; 86(4): 903 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Debette, S. Bevan, J.-F. Dartigues, M. Sitzer, M. Lorenz, P. Ducimetiere, P. Amouyel, and H. S. Markus Fractalkine Receptor/Ligand Genetic Variants and Carotid Intima-Media Thickness Stroke, June 1, 2009; 40(6): 2212 - 2214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Sullivan, J. L. Pardieck, D. Doran, Y. Zhang, J.-X. She, and J. S. Pollock Greater fractalkine expression in mesenteric arteries of female spontaneously hypertensive rats compared with males Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H1080 - H1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Landsman, L. Bar-On, A. Zernecke, K.-W. Kim, R. Krauthgamer, E. Shagdarsuren, S. A. Lira, I. L. Weissman, C. Weber, and S. Jung CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival Blood, January 22, 2009; 113(4): 963 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rodero, Y. Marie, M. Coudert, E. Blondet, K. Mokhtari, A. Rousseau, W. Raoul, C. Carpentier, F. Sennlaub, P. Deterre, et al. Polymorphism in the Microglial Cell-Mobilizing CX3CR1 Gene Is Associated With Survival in Patients With Glioblastoma J. Clin. Oncol., December 20, 2008; 26(36): 5957 - 5964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zernecke, E. Shagdarsuren, and C. Weber Chemokines in Atherosclerosis: An Update Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1897 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zanchi, C. Zoja, M. Morigi, F. Valsecchi, X. Y. Liu, D. Rottoli, M. Locatelli, S. Buelli, A. Pezzotta, P. Mapelli, et al. Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin J. Immunol., July 15, 2008; 181(2): 1460 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Saederup, L. Chan, S. A. Lira, and I. F. Charo Fractalkine Deficiency Markedly Reduces Macrophage Accumulation and Atherosclerotic Lesion Formation in CCR2-/- Mice: Evidence for Independent Chemokine Functions in Atherogenesis Circulation, April 1, 2008; 117(13): 1642 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Bolovan-Fritts and S. A. Spector Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction Blood, January 1, 2008; 111(1): 175 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Coll, S. Parra, C. Alonso-Villaverde, G. Aragones, M. Montero, J. Camps, J. Joven, and L. Masana The Role of Immunity and Inflammation in the Progression of Atherosclerosis in Patients With HIV Infection Stroke, September 1, 2007; 38(9): 2477 - 2484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Barlic and P. M. Murphy Chemokine regulation of atherosclerosis J. Leukoc. Biol., August 1, 2007; 82(2): 226 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Barlic, Y. Zhang, and P. M. Murphy Atherogenic Lipids Induce Adhesion of Human Coronary Artery Smooth Muscle Cells to Macrophages by Up-regulating Chemokine CX3CL1 on Smooth Muscle Cells in a TNF{alpha}-NF{kappa}B-dependent Manner J. Biol. Chem., June 29, 2007; 282(26): 19167 - 19176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Perros, P. Dorfmuller, R. Souza, I. Durand-Gasselin, V. Godot, F. Capel, S. Adnot, S. Eddahibi, M. Mazmanian, E. Fadel, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension Eur. Respir. J., May 1, 2007; 29(5): 937 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Morgan, H. M. Krumholz, R. P. Lifton, and J. A. Spertus Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study JAMA, April 11, 2007; 297(14): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schafer, C. Schulz, D. Fraccarollo, P. Tas, M. Leutke, M. Eigenthaler, S. Seidl, P. Heider, G. Ertl, S. Massberg, et al. The CX3C Chemokine Fractalkine Induces Vascular Dysfunction by Generation of Superoxide Anions Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 55 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ancuta, J. Wang, and D. Gabuzda CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J. Leukoc. Biol., November 1, 2006; 80(5): 1156 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Liu, S. Patil, M. Rojas, A. M. Fong, S. S. Smyth, and D. D. Patel CX3CR1 Deficiency Confers Protection From Intimal Hyperplasia After Arterial Injury Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2056 - 2062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Wallace, R. W. Vaughan, E. Kondeatis, R. Mathew, Y. Chen, E. M. Graham, and M. R. Stanford A CX3CR1 Genotype Associated with Retinal Vasculitis in Patients in the United Kingdom. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2966 - 2970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Norata, K. Garlaschelli, M. Ongari, S. Raselli, L. Grigore, and A. L. Catapano Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Thickness Stroke, June 1, 2006; 37(6): 1558 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, S. R. Green, F. Almazan, and O. Quehenberger The Amino Terminus and the Third Extracellular Loop of CX3CR1 Contain Determinants Critical for Distinct Receptor Functions Mol. Pharmacol., March 1, 2006; 69(3): 857 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Davis and J. K. Harrison Proline 326 in the C Terminus of Murine CX3CR1 Prevents G-Protein and Phosphatidylinositol 3-Kinase-Dependent Stimulation of Akt and Extracellular Signal-Regulated Kinase in Chinese Hamster Ovary Cells J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 356 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Damas, A. Boullier, T. Waehre, C. Smith, W. J. Sandberg, S. Green, P. Aukrust, and O. Quehenberger Expression of Fractalkine (CX3CL1) and its Receptor, CX3CR1, Is Elevated in Coronary Artery Disease and Is Reduced During Statin Therapy Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2567 - 2572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E Pyke and M. E Tschakovsky The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function J. Physiol., October 15, 2005; 568(2): 357 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Quehenberger Thematic Review Series: The Immune System and Atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis J. Lipid Res., August 1, 2005; 46(8): 1582 - 1590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lavergne, J. Labreuche, M. Daoudi, P. Debre, F. Cambien, P. Deterre, P. Amarenco, C. Combadiere, and on Behalf of the GENIC Investigators Adverse Associations Between CX3CR1 Polymorphisms and Risk of Cardiovascular or Cerebrovascular Disease Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 847 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Hasegawa, S Sato, T Echigo, Y Hamaguchi, M Yasui, and K Takehara Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis Ann Rheum Dis, January 1, 2005; 64(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Bolovan-Fritts, R. N. Trout, and S. A. Spector Human Cytomegalovirus-Specific CD4+-T-Cell Cytokine Response Induces Fractalkine in Endothelial Cells J. Virol., December 1, 2004; 78(23): 13173 - 13181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Davis, V. Zujovic, and J. K. Harrison Viral Macrophage Inflammatory Protein-II and Fractalkine (CX3CL1) Chimeras Identify Molecular Determinants of Affinity, Efficacy, and Selectivity at CX3CR1 Mol. Pharmacol., December 1, 2004; 66(6): 1431 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Barlic, D. H. McDermott, M. N. Merrell, J. Gonzales, L. E. Via, and P. M. Murphy Interleukin (IL)-15 and IL-2 Reciprocally Regulate Expression of the Chemokine Receptor CX3CR1 through Selective NFAT1- and NFAT2-dependent Mechanisms J. Biol. Chem., November 19, 2004; 279(47): 48520 - 48534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. F. Charo and M. B. Taubman Chemokines in the Pathogenesis of Vascular Disease Circ. Res., October 29, 2004; 95(9): 858 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Simeoni, B. R. Winkelmann, M. M. Hoffmann, S. Fleury, J. Ruiz, L. Kappenberger, W. Marz, and G. Vassalli Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis Eur. Heart J., August 2, 2004; 25(16): 1438 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Daoudi, E. Lavergne, A. Garin, N. Tarantino, P. Debre, F. Pincet, C. Combadiere, and P. Deterre Enhanced Adhesive Capacities of the Naturally Occurring Ile249-Met280 Variant of the Chemokine Receptor CX3CR1 J. Biol. Chem., May 7, 2004; 279(19): 19649 - 19657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schafer, C. Schulz, M. Eigenthaler, D. Fraccarollo, A. Kobsar, M. Gawaz, G. Ertl, U. Walter, and J. Bauersachs Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion Blood, January 15, 2004; 103(2): 407 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Umehara, E. T. Bloom, T. Okazaki, Y. Nagano, O. Yoshie, and T. Imai Fractalkine in Vascular Biology: From Basic Research to Clinical Disease Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 34 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Lucas, C. Bursill, T. J. Guzik, J. Sadowski, K. M. Channon, and D. R. Greaves Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX3CR1 and Undergo Chemotaxis to the CX3C Chemokine Fractalkine (CX3CL1) Circulation, November 18, 2003; 108(20): 2498 - 2504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Barlic, J. M. Sechler, and P. M. Murphy IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1 Blood, November 15, 2003; 102(10): 3494 - 3503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hundhausen, D. Misztela, T. A. Berkhout, N. Broadway, P. Saftig, K. Reiss, D. Hartmann, F. Fahrenholz, R. Postina, V. Matthews, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion Blood, August 15, 2003; 102(4): 1186 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dorfmuller, F. Perros, K. Balabanian, and M. Humbert Inflammation in pulmonary arterial hypertension Eur. Respir. J., August 1, 2003; 22(2): 358 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Vogel Heads and Hearts: The Endothelial Connection Circulation, June 10, 2003; 107(22): 2766 - 2768. [Full Text] [PDF]
|
|
|
|
|
|
M. E. DeVries, H. Cao, J. Wang, L. Xu, A. A. Kelvin, L. Ran, L. A. Chau, J. Madrenas, R. A. Hegele, and D. J. Kelvin Genomic Organization and Evolution of the CX3CR1/CCR8 Chemokine Receptor Locus J. Biol. Chem., March 28, 2003; 278(14): 11985 - 11994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Combadiere, S. Potteaux, J.-L. Gao, B. Esposito, S. Casanova, E. J. Lee, P. Debre, A. Tedgui, P. M. Murphy, and Z. Mallat Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice Circulation, February 25, 2003; 107(7): 1009 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Balabanian, A. Foussat, P. Dorfmuller, I. Durand-Gasselin, F. Capel, L. Bouchet-Delbos, A. Portier, A. Marfaing-Koka, R. Krzysiek, A.-C. Rimaniol, et al. CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1419 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Abdi, T. Thi Bich Huong, A. Sahagun-Ruiz, P. M. Murphy, B. M. Brenner, E. L. Milford, and D. H. McDermott Chemokine Receptor Polymorphism and Risk of Acute Rejection in Human Renal Transplantation J. Am. Soc. Nephrol., March 1, 2002; 13(3): 754 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ludwig, T. Berkhout, K. Moores, P. Groot, and G. Chapman Fractalkine Is Expressed by Smooth Muscle Cells in Response to IFN-{gamma} and TNF-{alpha} and Is Modulated by Metalloproteinase Activity J. Immunol., January 15, 2002; 168(2): 604 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wayne Alexander Cytokine Receptor CX3CR-1 and Fractalkine: New Factors in the Atherosclerosis Drama? Circ. Res., August 31, 2001; 89(5): 376 - 377. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||